Pathophysiology of type 2 diabetes. by Scheen, André
335 
Acta Clinica Belgica, 2003; 58-6
PATHOPHYSIOLOGY OF TYPE 2 DIABETES
PATHOPHYSIOLOGY OF TYPE 2 DIABETES
 A. J. Scheen
Key-words : Adipose tissue, Adipocytokins, Insulin resistance, Insulin secretion, Obesity, Type 2 diabetes
–––––––––––––––
          Division of Diabetes,
     Nutrition and Metabolic Disorders, 
     Department of Medicine,
     CHU Sart Tilman,
     Liège, Belgium.
     Address for correspondence :
     A. J. Scheen
     Department of medicine
     CHU Sart Tilman (b35)
     B-4000 Liege 1
     Belgium
     Phone : 32-4-3667238
     Fax : 32-4-3667068
     E-mail : andre.scheen@chu.ulg.ac.be
Continuing Medical Education
ABSTRACT
Type 2 diabetes mellitus is a heterogeneous syndrome 
characterized by abnormalities in carbohydrate and fat 
metabolism. The causes of type 2 diabetes are multi-
factorial and include both genetic and environmental 
elements that affect beta-cell function and tissue (mus-
cle, liver, adipose tissue, pancreas) insulin sensitivity. 
Although there is considerable debate as to the relative 
contributions of beta-cell dysfunction and reduced in-
sulin sensitivity to the pathogenesis of diabetes, it is 
generally agreed that both these factors play important 
roles. However, the mechanisms controlling the inter-
play of these two impairments are unclear. A number of 
factors have been suggested as possibly linking insulin 
resistance and beta-cell dysfunction in the pathogenesis 
of type 2 diabetes. A majority of individuals suffering 
from type 2 diabetes are obese, with central visceral 
adiposity. Therefore, the adipose tissue should play 
a crucial role in the pathogenesis of type 2 diabetes. 
Although the predominant paradigm used to explain 
this link is the portal/visceral hypothesis giving a key 
role in elevated non-esterifi ed fatty acid concentrations, 
two new emerging paradigms are the ectopic fat storage 
syndrome (deposition of triglycerides in muscle, liver 
and pancreatic cells) and the adipose tissue as endocrine 
organ hypothesis (secretion of various adipocytokins, 
i.e. leptin, TNF-α, resistin, adiponectin, implicated in 
insulin resistance and possibly beta-cell dysfunction). 
These two paradigms constitute the framework for the 
study of the interplay between insulin resistance and 
beta-cell dysfunction in type 2 diabetes as well as bet-
ween our obesogenic environment and diabetes risk in 
the next decade. 
Over the last decade, major advances have been made 
in our understanding of the pathophysiology and molecu-
lar biology of type 2 diabetes (1,2). Type 2 diabetes is a 
bipolar disease characterized by a defect in both insulin 
secretion and insulin action whose complex interaction 
leads to a progressive increase of plasma glucose levels 
(3). It is also well established that the development of 
type 2 diabetes results from an interaction of a subject’s 
genetic makeup (4) and their environment, and that with 
the increasing prevalence of obesity, the prevalence of 
type 2 diabetes is reaching epidemic proportions (5) 
(Figure 1). Various organs play a crucial role in the 
pathophysiology of type 2 diabetes. Disruption of the 
cross-talk between endocrine pancreas, liver, skeletal 
muscle, adipose tissue and, presumably, gut and central 
nervous system may lead to alteration of glucose home-
ostasis and type 2 diabetes (Figure 2) (6,7).
While most patients with type 2 diabetes are over-
weight or obese (5), the role of fat was initially neglected 
in the pathophysiology of the disease (6). Its role was 
highlighted almost a decade ago, especially the interac-
tions of non-esterifi ed fatty acids (NEFA) with glucose 
metabolism (7). The crucial impact of fat distribution, 
especially the negative infl uence of intra-abdominal or 
visceral fat depot, is now largely recognized (8). More 
recently, the deleterious role of ectopic triglyceride 
storage in the development of defective insulin action 
and insulin secretion has been emphasized leading to 
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the concept of lipotoxicity (9). Finally, as discussed at 
the end of this review, adipose tissue can secrete various 
molecules that may interfere with glucose metabolism 
and insulin sensitivity, such as leptin, tumour necrosis 
factor (TNF)-α, resistin, adiponectin, … (10). 
 While it is clear that hyperglycaemia is associated 
with both insulin resistance and beta-cell dysfunction, 
there has been much debate over the past few decades 
regarding the relative importance and sequence of these 
two abnormalities. This disagreement over the relative 
importance of these two defects in type 2 diabetes is 
partly due to the fact that evaluation of insulin resistance 
and beta-cell dysfunction has frequently been done in 
isolation, thus not taking into account the fact that glu-
cose homeostasis is vitally dependent on a feedback sy-
stem (3). Once consideration is given to the presence of a 
tightly regulated feedback system incorporating the beta 
cell and the insulin-sensitive tissues (hyperbolic relation-
ship between insulin secretion and insulin sensitivity), it 
becomes abundantly clear that reductions in both insulin 
sensitivity and beta-cell function are present early in the 
course of the development of type 2 diabetes (3).
ROLE OF INSULIN RESISTANCE IN TYPE 
2 DIABETES 
Even if insulin exerts numerous different effects, so 
far insulin sensitivity has been considered mainly in the 
context of glucose metabolism, especially at the liver and 
muscle sites (11). The presence of insulin resistance in 
vivo can be evidenced during various dynamic tests such 
as an oral glucose tolerance test, an intravenous glucose 
tolerance test and a so-called euglycaemic hyperinsuli-
naemic clamp (12). Using the latter approach, it has been 
extensively demonstrated that insulin-mediated glucose 
disposal (essentially in the skeletal muscle) is largely 
reduced in patients with type 2 diabetes. Furthermore, 
the concomitant use of isotopes showed that hepatic glu-
cose production is insuffi ciently inhibited by insulin, 
thus demonstrating the presence of both muscular and 
hepatic insulin resistance. 
Despite tremendous advances in molecular biology 
and the continued identifi cation of increasingly more 
molecules involved in the insulin signaling cascade, the 
molecular mechanism (or mechanisms) that underlines 
the development of insulin resistance in subjects prone to 
develop type 2 diabetes still remains elusive (4). Genetic 
mutations associated with insulin resistance are rare and 
it seems unlikely that a single genetic alteration explains 
a large number of cases of insulin resistance among type 
2 diabetic patients. Rather, it is more likely that a number 
of different genes may contribute, some of which may 
be obesity genes. Three commonly encountered factors 
that infl uence insulin sensitivity and are apparently not 
genetically determined are aging, exercise and dietary 
constituents. However, even if the effects of age, exercise 
and diet are considered, there is still a large between-sub-
ject variation in insulin sensitivity that has to be related 


































































Figure 2 :  Contribution of endocrine pancreas, liver, skeletal muscle 
and adipose tissue in the pathogenesis of type 2 diabetes : emerging role 
of ectopic fat storage in liver, muscle and beta-cell and of adipose tissue 
as an endocrine organ releasing various adipocytokins in addition to 
non-esterifi ed fatty acids (NEFA) in presence of positive energy balance 
and obesity. . 
Figure 1 : Contribution of genetic predisposition and environment factors 
in the pathogenesis of type 2 diabetes and interplay between defective 
insulin secretion and insulin resistance leading to a vicious circle ex-
plaining the progression from impaired glucose tolerance (IGT) to type 
2 diabetes and the progressive aggravation of the disease.
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riation may be related to obesity, but more importantly 
to differences in body fat distribution (8). 
A vast majority of type 2 diabetic patients are over-
weight, and obesity undoubtedly plays a major role 
in the development of the disease (1-3, 5). While it 
is recognized that obesity is an important determinant 
of insulin sensitivity (12), body-fat distribution seems 
to be a critical aspect (8). Several groups have made a 
strong case that the intra-abdominally fat depot is the 
primary correlate of insulin sensitivity, while others have 
proposed that the central subcutaneous fat depot is the 
major factor determining a reduction in insulin sensi-
tivity. Obese individuals with most of their fat stored 
in visceral adipose depots generally suffer greater ad-
verse metabolic consequences than similarly overweight 
subjects with fat stored predominantly in subcutaneous 
sites. Excess abdominal fat mass is associated with an 
increased release of NEFA that may trigger a reduction 
in insulin sensitivity at both the hepatic and the muscular 
levels. In the liver, this results in an increased glucose 
output (essentially due to enhanced gluconeogenesis), 
a decreased insulin extraction and an increased VLDL 
production while in the skeletal muscle this results in a 
reduction in glucose oxidation and glucose storage as 
glycogen (so-called Randle’s effect) (1,7). Numerous 
insulin-resistant obese patients have also a so-called 
metabolic syndrome associating impaired glucose 
tolerance (or type 2 diabetes), dyslipidaemia and ar-
terial hypertension, all factors aggravating the risk of 
cardiovascular diseases (13). A fuller understanding of 
the biology of central obesity will require information 
regarding the genetic and environmental determinants of 
human fat topography and of the molecular mechanisms 
linking visceral adiposity to degenerative metabolic and 
vascular disease.
Long-term positive energy balance may lead not only 
to excess triglyceride depots in the adipose tissue, but 
also to ectopic triglyceride storage. The ability of the adi-
pocyte to function properly when engorged with lipid can 
lead to lipid accumulation in other tissues, reducing their 
ability to function and response normally. Liver steatosis 
is a common fi nding in obese subjects, especially in those 
with intra-abdominal fat depot, and non-alcoholic fatty 
liver disease is now considered as part of the metabolic 
syndrome associated to insulin resistance. In addition, 
intramuscular triglyceride levels are increased in obese 
subjects, and a close relationship has been repeatedly 
reported between the degree of ectopic intramyocellular 
triglyceride depot and the severity of muscular insulin 
resistance (14). Interestingly, ectopic fat accumulation in 
insulin-sensitive tissues may be associated with insulin 
resistance independent of overall obesity. However, the 
understanding of the causes and mechanisms underly-
ing fat accumulation in skeletal muscle and the liver are 
limited. Identifying why some individuals store fat in 
insulin-sensitive tissues, but others do not, may be of 
great importance for the development of new insulin-
sensitizing agents.
The role of counterregulatory hormones in the 
resistance to insulin in patients with type 2 diabetes 
remains unclear. Nevertheless, plasma glucagon levels 
are regularly increased in type 2 diabetic patients and 
this hormone could contribute to enhance gluconeoge-
nesis and hepatic glucose output, especially in presence 
of insulin defi ciency (1). Pharmacological attempts to 
decrease glucagon secretion led to substantial reduction 
in plasma glucose levels, arguing for a signifi cant role 
of this hormone in the development of hyperglycaemia 
in type 2 diabetes.
Finally, an haemodynamic hypothesis of insulin re-
sistance has also been put forward (1). Reduced number 
of muscle capillaries and impaired insulin-induced va-
sodilatation (essentially in the postprandial state) may 
contribute to increase the distance and to alter the insulin 
diffusion process from the capillary to the muscular cells 
and thereby insulin action in obese patients with type 2 
diabetes (1). This circulatory phenomenon may explain 
recent consistent fi ndings showing that inhibition of 
the renin-angiotensin system (with either angiotensin 
converting enzyme inhibitors or AT1 receptor antago-
nists) is able to reduce the incidence of type 2 diabetes 
in hypertensive insulin-resistant patients.
 
ROLE OF INSULIN DEFICIENCY IN TYPE 
2 DIABETES
Beta-cell function in type 2 diabetes has been the 
subject of intense investigation for several decades, 
and considerable progress has been made during the 
recent years in the knowledge of the physiology and 
pathophysiology of insulin secretion (15). Recent data 
demonstrated that beta-cell defi cit and beta-cell apop-
tosis are present in humans with type 2 diabetes (16). 
Given the number of variables that could contribute to a 
disordered insulin secretory response, it is obvious that 
a precise defi nition of the sequence of events that leads 
to this disorder in a given patient with common type 2 
diabetes remains, in most cases, an elusive goal.
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Once hyperglycaemia exists, beta-cell dysfunction 
is clearly present in subjects with type 2 diabetes. This 
change manifests in a number of different ways including 
decreases in the early insulin response to intravenous or 
oral glucose and a decline in the ability of glucose to 
potentiate the insulin response to non-glucose secretago-
gues (15). Individuals with type 2 diabetes show also a 
decease in the potentiation by oral rather than parenteral 
glucose loading, a phenomenon known as the “incretin 
effect” which is associated to glucose-dependent in-
sulinotropic peptide (GIP) and glucagon-like peptide 
(GLP)-1 secreted by enterocytes. In addition, alterati-
ons in pulsatile insulin release and ultradian oscillatory 
insulin secretion can be observed. Finally, ineffi cient 
proinsulin processing to insulin and a reduction in the 
release of islet amyloid polypeptide (IAPP, also known 
as amylin) have been observed in established type 2 
diabetes (3). 
Recent examination of a number of different para-
meters in various human models has emphasised the 
fact that beta-cell dysfunction, when assessed using 
appropriate methods, is present well before the onset of 
hyperglycaemia, i.e. in subjects with impaired glucose 
tolerance and even in fi rst-degree relatives with normal 
glucose tolerance. First-phase insulin response to glucose 
is reduced in an early stage, thus contributing to post-
prandial hyperglycaemia, while late-phase insulin secre-
tion may be preserved for a longer term as it is triggered 
by sustained hyperglycaemia. A backward extrapolation 
of fi ndings made in the United Kingdom Prospective 
Diabetes Study (UKPDS) cohort from shortly after the 
clinical diagnosis of type 2 diabetes strongly suggests 
that beta-cell dysfunction commences years (at least 10 
years) before hyperglycaemia develops (17). 
Three main mechanisms have been proposed to ex-
plain the B-cell defi ciency observed in subjects prone to 
develop type 2 diabetes (1). First, a genetic defect may be 
present, although such a defect has not been detected yet 
in subjects with common type 2 diabetes associated with 
obesity, in contrast to what was reported in some parti-
cular forms of “Maturity-Onset Diabetes of the Youth” 
(MODY) (mutation of the glucokinase gene in MODY 
3, for instance) (15). Second, in utero malnutrition may 
lead to insuffi cient beta-cell development and later par-
tial insulin secretory defect. This hypothesis has been 
called the “thrifty phenotype hypothesis” (18). However, 
the relationship with insulin secretion seems to be less 
clear than the relationship with insulin resistance and the 
metabolic syndrome. And third, unfavourable metabolic 
environment may also play a deleterious role, especially 
increased glucose levels that may induce glucotoxicity 
(19) and a chronic increase in NEFA levels that may 
induce lipotoxicity (9), both processes contributing to al-
ter insulin secretion. Interestingly, ectopic deposition of 
triglycerides in pancreatic islets has also been reported, a 
condition that may contribute to dysfunction of the beta 
cell (9). Indeed, although the mechanism of lipotoxicity 
in the beta cell remains unclear, it has been suggested 
that accumulation of triglycerides increases nitric oxide, 
which causes oxidative damage and apoptosis in the 
cells (9). Finally, defects in insulin signalling pathways 
associated with insulin resistance in peripheral tissues 
have recently been found to disrupt insulin secretion by 
pancreatic beta cells, suggesting that insulin resistance 
in the beta cells may be, at least partly, responsible for 
the beta-cell dysfunction and the development of type 
2 diabetes (10).
DYNAMIC INTERACTION BETWEEN 
INSULIN ACTION AND INSULIN 
 SECRETION
Subjects with type 2 diabetes are characterized 
by both tissue insulin resistance and impaired insulin 
secretion (3,20). The development of diabetes requires 
the presence of these two fundamental defects, which 
disrupt the delicate balance by which insulin-target tis-
sues communicate with the beta cells and vice versa. 
Numerous observations underscore the important in-
terplay between insulin resistance and insulin secretion 
(1,3). Both abnormalities must be looked at in concert 
and the relative importance of these two factors can be 
estimated with the aid of a theoretical mathematical 
model of glucose metabolism. Insulin resistance alone 
is, in most instances, insuffi cient to cause overt glu-
cose intolerance. To observe the development of frank 
diabetes mellitus, a defect in insulin secretion must be 
superimposed on insulin resistance (1,3), and numerous 
observations suggest that this beta-cell defect might be 
genetically determined (21).
Type 2 diabetes occurs as a late phenomenon in obese 
subjects and is preceded by years of normal glucose 
tolerance or impaired glucose tolerance (IGT) as sug-
gested by several cross-sectional studies (1,3,8). The 
progression from IGT to diabetes occurs when the beta 
cell becomes unable to maintain its previously high rate 
of insulin secretion in response to glucose (22). Lon-
gitudinal studies confi rmed that this evolution occurs 
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along the natural history of obesity (8,22). During the 
fi rst years of obesity, the subjects are normoglycaemic 
but hyperinsulinaemic. Afterwards they become hy-
perglycaemic at a time when hyperinsulinaemia is not 
maintained anymore. To some extent, the natural history 
of the obese subjects developing type 2 diabetes after a 
prolonged phase of compensatory hyperinsulinism may 
be explained by the “overworked beta cell” hypothesis, 
an hypothesis supported by observations in various 
animal models (23).
Once it develops, either from insulin defi ciency or 
from insulin resistance, hyperglycaemia will exacerbate 
both defects, thereby closing a pathological feedback 
loop (Figure 1). Recent data from the UKPDS de-
monstrated that in newly diagnosed type 2 diabetes, 
the progressive deterioration of blood glucose control 
over the next 10 years can essentially be explained by a 
linear decrease of beta-cell insulin secretory capability 
(17). Even though our understanding of the mechanisms 
leading to the appearance and the progression of type 2 
diabetes is incomplete, the counterproductive interplay 
between insulin resistance and insulin defi ciency, and 
the concepts of glucose (19) and lipid (9) toxicity have 
important clinical and therapeutical implications (24). 
In the scenario of “glucose toxicity” or “glucose de-
sensitization” (19), glucose lowering is associated with 
improvements in both insulin action and insulin release. 
In the scenario of lipotoxicity (9), reduction in NEFA 
concentrations and ectopic fat storage after sustained 
negative energy balance and weight loss may also result 
in both enhanced insulin sensitivity and insulin secretion 
(8,22). Consequently, aggressive treatment targeted to 
even modest hyperglycaemia and weight excess should 
be recommended in order to slow down the development 
and progression of type 2 diabetes.
While most investigators agree that insulin secretion 
and insulin action must both be impaired for the deve-
lopment of overt diabetes, there is no consensus as to 
which comes fi rst (3, 20). Owing to increasing evidence 
of heterogeneity of the disease, it is plausible that each 
defect will prove to be primary in some forms of type 
2 diabetes. The answer will most certainly be provided 
by genetic analysis. Indeed, genetic research of type 2 
diabetes is undergoing rapid development, and many 
studies are in progress, especially using genome-wide 
scans which may lead to new genes. However, despite 
exciting developments, the genetic susceptibility of com-
mon type 2 diabetes still remains an enigma. 
ADIPOSE TISSUE AS AN ENDOCRINE 
ORGAN 
The view of the adipocyte as a simply storage depot 
for fat is no longer tenable. Indeed, the role of adipose 
tissue as an endocrine organ capable of secreting a 
number of adipose- tissue-specifi c or enriched hormo-
nes, known as adipocytokines or adipokines, is gaining 
appreciation. Indeed, besides NEFA, adipocytes secrete 
various cytokines, among which leptin, TNF-α, resistin 
and adiponectin (9,10,14). The role of leptin in carbo-
hydrate metabolism remains unclear whereas TNF-α 
and resistin clearly inhibit cellular insulin action (10). 
However, most studies were performed in rodents and 
the contribution of these two cytokines to hyperglycae-
mia of type 2 diabetes is still controversial in humans. 
Among the various adipocytokines, adiponectin appears 
to play a very important role in carbohydrate and lipid 
metabolism (25). Indeed, adiponectin, an abundant 
circulating protein synthesized solely in adipose tissue, 
appears to be a major modulator of insulin action. In 
contrast to other adipocytokines, adiponectin is charac-
terized by lower (and not higher) circulating levels in 
presence of obesity. In addition, whereas leptin is more 
positively related to subcutaneous than to intra-abdomi-
nal fat, adiponectin is more strongly negatively related 
to intra-abdominal than to subcutaneous fat. Its levels 
are reduced in type 2 diabetes and a strong positive re-
lationship between insulin sensitivity and adiponectin 
levels has been described in various populations. Thus, 
low adiponectin levels could contribute to peripheral 
insulin resistance in type 2 diabetes. The mechanisms by 
which adiponectin is synthesized need to be elucidated, 
as do the signals that reduce adiponectin expression 
in adipocytes with increasing adiposity. Similarly, the 
molecular mechanisms by which adiponectin exerts its 
multiple functions still remain a mystery as well as its 
potential role in the development of type 2 diabetes in 
obese subjects, especially those with intra-abdominal 
adiposity. Although further investigations are required, 
adiponectin administration, as well as regulation of the 
pathways controlling its production (new insulin sensiti-
zers thiazolidinediones, also called glitazones, have been 
shown to increase adiponectin concentrations) represents 
a promising target for managing insulin resistance and 
type 2 diabetes (25).
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CONCLUSIONS
The development of type 2 diabetes requires the pre-
sence of two fundamental defects, i.e. insulin resistance 
and impaired insulin secretion, which disrupt the delicate 
balance by which insulin target tissues communicate 
with the beta cells and vice versa. Thus, type 2 diabetes 
is a heterogeneous disorder characterized by impaired 
insulin secretion, diminished peripheral (muscular) insu-
lin action, and increased hepatic glucose production, all 
defects being present in variable proportions in different 
individuals, but also prone to changes in a given indi-
vidual with the progression of the disease. Recent data 
from UKPDS and other studies clearly showed that the 
progression of hyperglycaemia characterizing the natu-
ral history of type 2 diabetes essentially results from an 
aggravation of beta-cell defect. Thus, besides efforts to 
correct insulin resistance, preserving beta-cell function 
represents a key-objective for the future management of 
type 2 diabetes (26). 
Obesity, especially intra-abdominal adiposity, plays a 
crucial role in the development of the disease. Numerous 
mechanisms have been proposed including elevated 
NEFA circulating levels, ectopic fat storage exerting a 
toxic effect in liver, muscle and pancreas, and secretion 
of various adipocytokins that may interfere with insulin 
action and possibly insulin secretion. In addition, all the 
abnormalities linked to fat tissue are intimately associ-
ated with the so-called metabolic syndrome frequently 
observed in obese individuals with type 2 diabetes who 
are at high risk of cardiovascular diseases.
Even though we are not yet able to pinpoint the pri-
mary defect in most patients with type 2 diabetes, there 
appears to be a counterproductive interplay between 
beta-cell inadequacy and insulin resistance, which leads 
to a vicious circle that perpetuates and aggravates the 
metabolic disorder. Based on our greater understanding 
of the relative roles of insulin resistance and beta-cell 
dysfunction in type 2 diabetes and the increasingly re-
cognized role of adipose tissue and ectopic fat storage, 
we can anticipate advances in the identifi cation of genes 
contributing to the development of the disease as well 
as approaches to the treatment and prevention of type 
2 diabetes. 
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